



**FIND Evaluation of SD Biosensor, Inc.**  
**STANDARD Q COVID-19 Ag Test**  
**External Report**  
*Version 1.0, 18 September 2020*

**Copyright and use of the report**

Copyright in this report is the property of FIND (or controlled by FIND). You are free to share, copy and redistribute the material in any medium or format provided that:

- (i) attribution: you must give appropriate credit to FIND and indicate if changes were made, you may do so in any reasonable manner, but not in any way that suggests that FIND endorses you or your use;
- (ii) non-commercial: you may not use the report for commercial purposes; and
- (iii) no derivatives: if you remix, transform, or build upon the materials or report, you may not distribute the modified materials or report unless with express authorization from FIND.

Presentation of data on our website does not impact any data ownership rights and FIND is not responsible for any use by any third party of these data. Data sources are provided.

**Evaluation Process – private sector engagement**

FIND is a non-for-profit foundation, whose mission is to find diagnostic solutions to overcome diseases of poverty in lower- and middle-income countries. It works closely with the private and public sectors and receives funding from donors and some of its industry partners. It has internal fire walls, policies and processes to protect it against any undue influence in its work or the publication of its findings.

More information on our policy and guidelines for working with private sector partners can be found here: <https://www.finddx.org/policies/>

For the COVID-19 response, FIND has commissioned independent evaluations of in vitro diagnostics following an Expression of Interest (EOI) process available on FIND's webpage by which all test submissions were scored according to their regulatory status and time to market; the manufacturing and distribution capacity of the supplier; and the supplier-reported clinical and analytical performance.

**Document History**

Document Version	Date	Comment
1.0	18 September 2020	Initial release

## 1 Product Info:

Manufacturer Name	SD Biosensor, Inc.
Test name	STANDARD Q COVID-19 Ag Test
Product Code(s)	09COV30D
Pack size(s)	25 tests per kit
Contents of kit	Test device (individually in a foil pouch with desiccant), Extraction buffer tube, Nozzle cap, Sterile swab, Film and Instructions for Use
Equipment and consumables required, but not provided	Equipment: Timer, refrigerator - optional (for storage of specimens prior to testing, if applicable). Consumables: PPE
Product Storage (temperature range)	2-30 °C.
Shelf-life (months)	24 months
Manufacturing Site (country)	Republic of Korea

## 2 Study details:

Study design:	Prospective diagnostic evaluation studies across multiple, independent sites to determine the accuracy of COVID-19 antigen RDTs, using consecutive enrolment. Interim analyses are performed at 25% and 50% enrolment, and the evaluation is stopped if tests do not meet 97% specificity. Presence of symptoms, date of symptom onset and hospitalization status is collected for all enrolled participants.
Index assays:	Novel lateral flow format tests that detect recombinant SARS-CoV-2 antigens.
Reference method:	Results of the index test are compared to the routine, diagnostic RT-PCR result, which is used for clinical management
Limit of detection:	Analytical sensitivity, i.e. Limit of detection, was performed at the Liverpool School of Tropical Medicine and/or the Institute of Virology, Charité-Universitätsmedizin Berlin in which standardized serial dilutions of cultured viral isolate were prepared. Dilutions were done in triplicate and the LOD was defined as the last dilution where all repeats were interpreted as positive.
Clinical Performance:	Sensitivity was calculated as the proportion of true positive results detected by STANDARD Q COVID-19 Ag among all positives by the reference method, and reported as a percentage

	<p>Specificity was calculated as the proportion of true negative specimens, identified as negative by STANDARD Q COVID-19 Ag among all negatives by the reference method, and reported as a percentage.</p> <p>The 95% confidence intervals were calculated in order to assess the level of uncertainty introduced by sample size, using the Wilson's score method.</p>
Ease of Use	<p>A System usability survey and ease of use questionnaire assessing the quality of the test, test preparation, ease of test execution, procedure time, ease of result interpretation, storage conditions and perceived settings of use was completed by operators and a final score out of 100 was calculated.</p>

### 3 Evaluation Details

Country of Collaborator	Germany	Brazil
Location of clinical site(s) (city, town)	<ol style="list-style-type: none"> <li>1. Heidelberg (HD)</li> <li>2. Berlin</li> </ol>	Macaé, state of Rio de Janeiro
Health care level of site(s)	<ol style="list-style-type: none"> <li>1. Heidelberg: Drive-in testing Center</li> <li>2. Berlin: Ambulatory testing clinic of Charité – University Hospital</li> </ol>	Community Testing Clinic
Study period (date to date)	<ol style="list-style-type: none"> <li>1. HD: 20-31 July</li> <li>2. Berlin: 03 June -31 July</li> </ol>	13-30 July
Study cohort inclusion/exclusion	<p>Adults able to ambulate and meeting suspect definition of the Department of public health</p> <p>Provided informed consent</p>	<p>Adults in community meeting national suspect definition</p> <p>Provided informed consent</p>
Sample type, antigen test	<ol style="list-style-type: none"> <li>1. HD: Nasopharyngeal swabs</li> <li>2. Berlin: Combined nasopharyngeal swab</li> </ol> <p>Proprietary swab/media provided by SD Biosensor</p>	<p>Nasopharyngeal swabs</p> <p>Proprietary swab/media provided by SD Biosensor</p>
Reference PCR Method	<ul style="list-style-type: none"> <li>• Cobas SARS-CoV-2 (Roche Diagnostics Inc)</li> <li>• Abbott <i>RealTime</i> SARS-CoV-2 (Abbott Molecular, Inc)</li> <li>• Genesig COVID-19 Real-Time PCR assay (Primerdesign, Inc),</li> <li>• Allplex 2019-nCov Assay (Seegene Inc)</li> <li>• LightMix® Modular SARS-CoV (COVID19) E-gene (Tib Molbiol)</li> </ul>	<ul style="list-style-type: none"> <li>• Lab-developed assay based on the US CDC protocol, which targets two regions (N1 and N2) of the nucleocapsid (N) gene of SARS-CoV-2 (<a href="https://www.fda.gov/media/134922/download">https://www.fda.gov/media/134922/download</a>)</li> </ul>

Sample type, PCR test	naso/oropharyngeal swabs	oropharyngeal swabs
-----------------------	--------------------------	---------------------

## 4 Results

### 4.1 Study Cohort(s)

Country	Germany	Brazil
Total N (valid PCR results)	1259	400
Age [mean (min-max), N]	35 (18-80.4); 1242	37 (2-94); 397
Gender [%F, (n/N)]	48.9%, (616/1222)	57.3%, (229/398)
Symptoms present [%Yes, (n/N)]	84.7%, (1039/1227)	98.7%, (392/397)
Hospitalized (n, % Yes)	unknown	unknown
Days from symptom onset [median (Q1-Q3); N]	3 (2-4); 1002	5 (4-6); 397
Days < 0-3 (n, %)	628 (62.7%)	85 (21.4%)
Days 4-7 (n, %)	310 (30.9%)	273 (68.8%)
Days 8+ (n, %)	64 (6.4%)	39 (9.8%)
Positivity [%, (n/N)]	3.7%, (47/1259)	26.5%, (106/400)
PCR Ct [median (Q1-Q3); N]	25.3 (21.8-29.1); 47	25.5 (22.8-29.2); 106
Ct > 33 (n, %)	6 (12.8%)	7 (6.6%)
Ct > 30 (n, %)	11 (23.4%)	19 (17.9%)
Ct > 25 (n, %)	26 (55.3%)	57 (53.8%)

### 4.2 Estimation of Clinical and Analytical Performance

Country	Germany	Brazil
Clinical Sensitivity (95% CI); N	76.6% (62.8, 86.4); 47	88.7% (81.3, 93.4); 106
Sensitivity days ≤7, N	80% (64.1, 90.1); 35	90.7% (83.3, 95.0); 97
Sensitivity Ct ≤33, N	87.8% (74.5, 94.7); 41	91.9% (84.9, 95.9); 99
Sensitivity Ct ≤ 25, N	100% (84.5, 100); 21	95.9% (86.3, 98.9); 49
Clinical Specificity (95% CI), N	99.3% (98.6, 99.6); 1212	97.6% (95.2, 98.8); 294



Invalid rate (% , n/N)	0%, 0/1259	0%, 0/400
Analytical Sensitivity (pfu/ml) <sup>1</sup>	5.0 x 10 <sup>3</sup> pfu/ml ~ 7.14 x 10 <sup>3</sup> TCID <sub>50</sub> /ml	

<sup>1</sup> The claimed LOD by the supplier is 3.06 x 10<sup>2.2</sup> TCID<sub>50</sub>/ml, which is the equivalent of approximately 3.9 x 10<sup>2</sup> pfu/ml. Therefore, we verify the LOD to be 10-fold higher than that found by the supplier, using a different viral strain.

#### 4.3 Ease of Use

STANDARD Q COVID-19 Ag Test (SD Biosensor, Inc.)	86 out of 100	6 operators, Germany 1 operator, UK
--	---------------	--